News & Events

The development of innovative immunotherapy approaches for cancers and autoimmune disorders among others, remains a top priority for Biopharma however numerous challenges create hurdles to progress. To begin with, there is a requirement for multi-faceted, high-parameter, single cell readouts from limited sample inputs to identify informative biomarker signatures. Furthermore, the complex nature of the underlying […]

Dr. Nasry Yassa, CEO and Andrew Brown, Chief Commercial Officer, discuss the use of Fluidigm Mass Cytometry technology within their specialty contract research organization. They have created a specialized CRO business that partners with biopharma to accelerate drug development work, with a focus on introducing novel technologies into early clinical stage development. At this event […]

We have implemented advanced microfluidics technology to enable rapid, accurate, lower cost COVID-19 testing on easy to collect saliva samples. The Advanta™ SARS-CoV-2 RT-PCR assay was developed by Fluidigm and is supported by an EUA. The assay is a reverse transcription and real-time polymerase chain reaction (RT-PCR) test that leverages Fluidigm microfluidics technology with the […]

Sirona Dx is a Portland, Oregon-based technical contract research organization (CRO), which provides high-complexity genomics and proteomics services to pharmaceutical and biotech companies to support drug discovery and development in immuno-oncology. Sirona Dx recently brought the CODEX platform on board to support discovery research with single-cell, spatially resolved multiplex imaging. To learn how the CRO is accelerating […]

Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical research SOUTH SAN FRANCISCO, Calif. and PORTLAND, Ore., Nov. 01, 2018 (GLOBE NEWSWIRE) — Sirona Dx, a leader in high-complexity genomics and proteomics services, today announced the introduction of Imaging Mass Cytometry™ services on the Fluidigm Hyperion™ Imaging System to advance biomarker discovery and […]

PORTLAND, Ore., Oct. 30, 2018 /PRNewswire/ — Sirona Dx, a leader in high complexity genomics and proteomics services, announced today the launch of Oncocyst PD-L1, an assay using IncellDx technology that detects and quantifies abnormal bladder cells and immune cells from urine cytology specimens that express the immune-oncology marker PD-L1 using multi-parameter flow cytometry and […]